Background: The oxidative burden in the airways is a hallmark of chronic obstructive pulmonary disease (COPD). Aims: This prospective, cross-over, placebo (PL) controlled study was designed to investigate the effect of N-acetyl-L-cysteine (NAC) on hydrogen peroxide (H 2 O 2 ), nitrites/nitrates (NO 2 -+NO 3 -) and thiol (RSH) concentrations in exhaled breath condensate (EBC) in stable COPD patients (n=19, aged 52.6±15.6 years, 10 females, mean FEV 1 95.2±23.8%, FEV 1 /FVC 69.1±11.4%). Methods: H 2 O 2 , NO 2 -+NO 3 and RSH concentrations in EBC were determined with homovanillic acid, NADPH-nitrite reductase assays and Ellman's reaction, respectively. Results: Thirty minutes after nebulization, H 2 O 2 concentration increased if levels after NAC (0.45±0.25 µM) and PL (0.17±0.17 µM) were compared in COPD patients (p=0.002). This increased H 2 O 2 level in EBC was no longer observed either after ninety minutes: 0.16±0.09 µM (PL 0.17±0.15 µM) or three hours: 0.12±0.07 µM (PL 0.21±0.23 µM) (p=0.5 and p=0.2, respectively). The levels of NO 2 and NO 3 did not differ between NAC and PL. There was no significant difference in RSH levels between nebulized NAC and PL. After nebulized NAC, however, exhaled RSH increased from 1.42±1.69 µM (0 min) to 2.49±2.00 µM (30 min,) and 1.71±1.83 µM (180 min) (p=0.009 and p=0.03, respectively, compared with 0 min). Conclusions: These data demonstrate that nebulized NAC transiently increases exhaled H 2 O 2 level, whereas it has no effect on other oxidative parameters.
Introduction
The oxidative burden in the airways is a hallmark of chronic obstructive pulmonary disease (COPD). Generation of reactive oxygen (ROS) and nitrogen species (RNS) coincides with increased lipid peroxidation, alveolar injury, increased endothelial permeability and extracellular matrix turnover, extensive mucus secretion and accumulation of activated macrophages and polymorphonuclear leukocytes [1] . Redox sensitive inflammatory transcription factors upregulated in the oxidative milieu may alter chromatin structure accounting for attenuation of inhaled steroid efficiency in COPD patients [2] . The increased nitrotyrosine and heme oxygenase and myeloperoxidase activities are specifically associated with COPD exacerbation [3] . The progressive deterioration of lung function and oxidative damage of lung parenchyma has an insidious time pattern and antioxidant approaches to COPD therapy have long now been considered as a likely beneficial option [1] .
Nitric oxide (NO) is generated by sequestrated polymorphonuclear leukocytes and activated macrophages in the course of chronic inflammatory reaction in the lungs of COPD patients [4] .
Its oxidation is terminated with nitrites and nitrates as stable end products. NO readily reacts with superoxide to from peroxynitrite (ONOO -) anion. It may initiate a set of reactions leading to extensive oxidative damage of histone deacetylase, antiproteases, surfactant, membrane lipids and the injury of alveolar epithelium [5] . Also, ONOOformation leads to nitration and oxidation of protein sulfhydryl groups of the reduced cysteine and intracellular glutathione [6] along with 3 A c c e p t e d m a n u s c r i p t the inhibition of antioxidant enzymes in a dose-dependent manner [7] . The levels of NO in exhaled air were demonstrated to correlate with accumulation of inflammatory cells and the functional indices of COPD exacerbation [8] . Exhaled breath condensate (EBC) is considered suitable for the assessment of airway inflammatory reactions [9] and nitrates levels in EBC were demonstrated to differ specifically in various diseases including asthma, COPD or community acquired pneumonia [10] .
Several lines of evidence demonstrate the increased levels of H 2 O 2 in the airways of COPD patients [1] . The increased H 2 O 2 concentration in EBC was found in stable COPD patients [11, 12] and in the acute exacerbation [13] . The role of H 2 O 2 may likely extend far beyond relatively stable ROS end product and oxidative injury parameter. H 2 O 2 may act as a second messenger, sometimes in concert with NO, and may regulate redox state of cysteine residues of signaling proteins including tyrosine kinase, PTEN and Ras [6] . The mean EBC H 2 O 2 level in COPD patients were 10 times higher than in healthy subjects, although it varied in a wide range [12, 13] . The oral administration of NAC was demonstrated to decrease exhaled H 2 O 2 in COPD patients [11, 14] . Albeit inhaled NAC was shown to reduce even baseline levels of exhaled H 2 O 2 in healthy subjects thirty minutes after its administration, the apparent increase of expired H 2 O 2 was noted three hours later indicating either pro-oxidant effects or a rebound, oxidative response to antioxidant deposition in the airways [15] .
NAC is a readily diffusible reductant aminothiol and a precursor of glutathione (GSH). The milimolar concentrations of intracellular GSH provide efficient scavenging of ROS and RNS.
NAC scavenges hydroxyl radical and rapidly reacts with hypochlorous acid, inhibits oxidation of myeloperoxidase targets [16] , exhibiting only a trace of affinity to H 2 O 2 and none to superoxide anion [17] . NAC is able to upregulate gene expression at a transcriptional level facilitating cytoskeleton rebuilding and cell cycle arrest [18] . In the animal model, NAC appeared to hamper A c c e p t e d m a n u s c r i p t the progressive destruction of lung parenchyma and emphysema elicited by the specific inhibition of tyrosine kinase activity of VEGF receptors and attenuated the oxidative stress [19] .
Albeit NAC in various route of administration indeed demonstrated appreciable benefits in COPD patients [20] , the antioxidant effects of nebulized NAC have not been investigated so far in the setting of stable, mild COPD. Since intravenous GSH in healthy volunteers increased the level of cysteine in the expired air [21] , it seems likely that inhaled NAC could increase airway GSH levels and improve antioxidant defense. The reagents were prepared freshly in deionized, pyrogen free water (resistance > 18 MΩcm, HPLC Water Purification System USF ELGA, England) and kept on ice prior to use.
Materials and Methods

Reagents and medications
Patients and study protocol
The study included 19 patients with COPD (10 women, aged 65±13; 9 men, aged 67±12) from municipal hospital COPD patient registry ( Table 1) . Each enrolled patient had to meet the following inclusion criteria: (1) stage 0, mild or moderate COPD diagnosis according to GOLD guidelines [22] , (2) chest X-ray consistent with the diagnosis, (3) patients requiring only short acting β-2-agonist. The exclusion criteria included: (1) COPD exacerbation within prior three months; (2) patients receiving N-acetylcysteine or ambroxol within four months before the study;
(3) bronchial asthma, cystic fibrosis, active tuberculosis, atopy, bronchiectasis, active malignancies; (4) creatinine clearance of below 30 ml/min; (5) alanine and aspartate aminotransferase or alkaline phosphatase serum levels three times above the normal levels; (6) patients requiring non-steroid anti-inflammatory drugs, theophylline, long-acting β-2-agonists, inhaled steroids or oxygen therapy; (7) immunodeficiency or concomitant medication including immune suppressors, systemic inflammatory disease; (8) pregnant or breast-feeding females; (9) alcohol, illicit drug abuse.
A c c e p t e d m a n u s c r i p t
The study subjects were asked to attend the lab twice and were randomly chosen in double blind manner to receive assigned study medication package containing either nebulized Fluimucil (300 mg in 3ml) or PL (3 ml) within two weeks' time. The dosage and dilution of nebulized Fluimucil preparation was according to common clinical practice and manufacturer's recommendations (Zambon Group, Italy) . The study protocol required lab staff to prepare solution for nebulization in a separate room and the delivery of the drug itself was conducted with the patient wearing a nose clip. EBC was collected before, 30, 90 and 180 min after either Fluimucil or PL inhalation.
Lung function tests were performed according to the American Thoracic Society standards [23] , initially during preselection phase, immediately before the first and just after the last EBC collection. The experiments started always between 8 30 and 9 00 and finished 13 20 -13 50 . Each patient involved in the study gave informed consent and the study protocol was thoroughly reviewed and approved by the Institutional Review Board at Medical University of Lodz.
Functional lung tests
Master-Laboratory Screen (Jaeger Toennies, Wuerzburg, Germany) was used for lung functional tests including FVC (forced vital capacity), FEV 1 (forced expiratory volume in the first second), DLCO c (single breath carbon monoxide diffusing capacity corrected for hemoglobin and alveolar volume), RV He (residual volume, helium dilution technique) according to the standard procedure [23, 24] and the results were expressed as percentage of predicted values [23, 25] .
Collection of exhaled breath condensate
The EBC specimens for H 2 O 2 assay were collected as previously described [15] . The amylase levels in EBC specimens were assayed as a control of salivary contamination with Vitros 250 assay (enzymatic test, lower detection limit 2 U/l, Johnson&Johnson, Ortho Clinical Diagnostics,
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A c c e p t e d m a n u s c r i p t USA). The patient respiratory rate during EBC collection ranged from 14 to 19 breaths per minute. The procedure of EBC collection was 20 minutes and the mean volume of EBC was 5 ml. The EBC samples were processed in the assays for H 2 O 2 and thiol content or were stored at -80ºC prior to nitrites/nitrates assays.
Measurement of H 2 O 2 in exhaled breath condensate
The concentration of H 2 O 2 in EBC was measured with previously described fluorometrical method [26, 27] . water instead of EBC) [26] . For standard hydrogen peroxide solutions ranging from 0.1 to 0.5 µM H 2 O 2 intra-assay variability did not exceed 2%. The detection limit of H 2 O 2 assay was 0.1 µM. The daily variability of H 2 O 2 assay in EBC was less than 15%. Among 152 H 2 O 2 assays in the study subjects, only four results were below the method sensitivity and they were assumed a half of detection limit for the purposes of data analysis.
Nitrites and nitrates assay in exhaled breath condensate
The modified method was used for the nitrites (NO 2 ‫-‬ ) and nitrates (NO 3
‫-‬
) assay with NADPHnitrite reductase [28] . EBC (60 µl) was added in duplicate into 96 well plates with control wells A c c e p t e d m a n u s c r i p t between groups were analyzed with Mann-Whitney U test or Friedman ANOVA test. The
Pearson correlation coefficient was used to assess the data interrelation. In all cases, a p value ≤ 0.05 was considered significant.
Results
Effect of nebulized N-acetylcysteine on lung function parameters in COPD patients
The baseline characteristics of the study subjects is presented in nebulized PL were considered a background, confounding factor and were subtracted from exhaled H 2 O 2 levels after nebulized NAC (Fig.1) . The H 2 O 2 levels in any given patient after PL A c c e p t e d m a n u s c r i p t were subtracted from respective H 2 O 2 levels after NAC to determine if there were actual differences between PL and NAC (Fig.1) . The levels of relative increase of exhaled H 2 O 2 were significantly higher 30 min after nebulized NAC (p=0.002). The time course of H 2 O 2 exhalation for up to three hours after the nebulized NAC and PL in COPD patients is presented in Table 2 .
Effect of N-acetylcysteine on the time course of nitrites and nitrates exhalation in COPD patients
The Fig. 2A and 2B . Table 3 ). The differences in RSH levels between nebulized NAC and PL were not significant. For detailed comparisons, see Figure 3 . The thiols content variability evaluated in the same subjects before either PL or NAC inhalation was 16%. In statistical terms, the differences between the same patients before PL and NAC nebulization were not significant.
Effect of N-acetylcysteine on the time course of thiol exhalation in COPD patients
Correlation between exhaled breath condensate parameters
Both 30 min. and 180 min. after nebulized NAC, there was significant, positive correlation between the EBC concentration of nitrates and RSH: r=0.67 and r=0.80; (p=0.02 and p=0.003), respectively. Further, the EBC concentrations of RSH and H 2 O 2 were significantly interrelated (r=0.78; p=0.003) 180 min after NAC nebulization. None of these relationships were noted after nebulized PL in the same subjects.
Discussion
The range of H 2 O 2 concentrations detected in our study patients is consistent with their clinical characteristics of mild or stage 0, stable COPD. The stable COPD subjects in our study presented with exhaled H 2 O 2 levels below those reported in moderate and severe COPD stage [11, 14] or COPD exacerbation [13] . EBC levels of H 2 O 2 in patients with more advanced, moderate COPD were previously shown to be 10 times higher than in healthy controls [12] . They are approximately twice higher than H 2 O 2 levels in COPD patient included into the present study and the current COPD H 2 O 2 levels are still 4 times higher than those reported in healthy subjects [12] . Oral N-acetylcysteine was demonstrated to decrease exhaled H 2 O 2 in stable COPD patients [11, 14] . Previously, the decreased exhaled H 2 O 2 levels were found 30 min after nebulized NAC
A c c e p t e d m a n u s c r i p t
in parallel with the significant levels of H 2 O 2 generated in NAC solution used for nebulization under in vitro conditions [15] . Inhaled NAC entirely inhibited H 2 O 2 exhalation half an hour and increased H 2 O 2 approximately twice three hours after its nebulization in healthy, non-smoking subjects [15] . Conversely, in the current patients with COPD, NAC increased exhaled H 2 O 2 half an hour later above the reference levels returning to baseline at later time points. If the increased H 2 O 2 level in the current study were due to the auto-oxidation in NAC solution, the increase could likely be noticeable not only 30 min. after nebulized NAC, but also on further time points, as in our former study [15] . The contribution of auto-oxidation in NAC solution would be most probably only minor after half an hour of its deposition in the airways. Therefore, it seems more credible that the temporary and short-lived H 2 O 2 increase is related with redox interactions in the airways of COPD patients.
The clinical attempts to evaluate the redox effects of drugs commonly encounter similar obstacles related with the biased understanding of the redox reactions and their relativity with respect to physical and chemical parameters. Also, it may be over simplistic to assume that NAC may have pro-oxidant side effects [20] . The redox potential of cysteine/cystine couple is reportedly high enough to oxidize corresponding glutathione GSH/GSSG couple and act not as an oxidant but as a critical intracellular redox control of protein activity [29] . NAC may increase H 2 O 2 levels mediating the increase of intracellular NO and provide an excess of thiol groups that redirect NO away from cellular targets and enhance ROS generation [30, 31] . Additionally, ROS may be generated in the aerobic lung environment in the reactions involving native or thiol bound NO and glutathione or cysteine [32] . and thiyl radicals •RS are generated by cysteine gradually decomposing S-nitrosogluthatione [32] and are capable of forming H 2 O 2 .
NAC may initiate and interfere with other specific reactions in the airways of COPD patients.
Thiol compounds (RSH), unlike ionized thiolates (RS -), do not react with H 2 O 2 [6] and it is unlikely non-ionized NAC would directly alter H 2 O 2 levels. Also, reaction of superoxide anion ·O 2 with RSH is probable in the airways but quite unlikely significant at the intracellular level due to rapid dismutation of ·O 2 - [6] . S-nitrosoglutathione and NAC derivative not only release NO but effectively increase the extend and selectivity of NO action. RSNO stabilizes NO reactivity and increases its half-life redirecting its target actions into more selective thioregulatory functions upon proteins [33] . The reaction between RNS and NAC initially involved the intermediates on the redox path to nitrates and nitrites. NAC may react with either nitrogen dioxide radical (·NO 2 ) as well as directly with nitric oxide or nitrogen trioxide (N 2 O 3 ) to from S-nitrosthiol [6] . Further, NAC may inhibit the heme oxygenase mediated oxidation and increase iron levels in COPD. The lung parenchyma overload with iron in smoking COPD patients may accelerate not only Fenton's reaction but also nitrosothiol formation in the reaction A c c e p t e d m a n u s c r i p t introsonim ion intermediate. Ionized thiol adduct with iron are characterized with the increased reactivity compared with native thiols [6] . Proximity of a redox metal to a target thiol may be an important factor in thiol nitrosylation. Finally, the forms of ionized thiolates (RS -) and thiyl radicals (•RS), including not only NAC but also GSH pools, in aerobic conditions from superoxide anion, eventually decomposing to hydrogen peroxide detected in our COPD patients.
The existing data on interrelation between lung functional and oxidative parameters in subjects with COPD provide evidence on the reverse relation between FEV 1 values and nitrotyrosine formation [4] . In the experimental setting with nebulized thiols, GSNO increased expired NO for up to 30 minutes in cystic fibrosis patients [34] . Reduced and oxidized glutathione and nitrosothiols were increased approximately twice in COPD patients but exhaled NO did not correlate with nitrosothiols [35] . NAC may function as an NO antagonist by providing an excess of thiol groups that redirect NO [31] . Nitrates and nitrites levels in EBC were related with increased exhaled levels of H 2 O 2 [36] and their increased levels in asthmatic patients were similar as those reported hereby [28] . Nitrates were elevated in smokers, whereas
were not reportedly increased in COPD patients [10] . Also, nebulization alone may accelerate droplet formation at epithelial lining fluid. Due to both decreased mucus viscosity and increased mucociliary clearance, more droplets from lower airways epithelial lining are blown away and moved upwards.
The existing clinical data on inhaled NAC confirm insignificant effects on forced expiratory parameters even if NAC did appear to improve exercise-induced desaturation in pulmonary fibrosis [37] . NAC recently turned out ineffective in reducing annual number of exacerbation and did not prevent from deteriorating FEV 1 in COPD patients in a randomized, placebo-controlled,
three-year study [38] . m a n u s c r i p t Apparently, the clinical significance of NAC nebulization in this group of patients merely exceeds placebo effects. Although the relevance of these observations remains yet to be established, this study provides some novel evidence on pro-oxidant effects of nebulized NAC.
Albeit these effects were short-lived and moderate in COPD patients, they may be specifically associated with increased thiol oxidative turnover further accelerated by NAC deposition in airways. The study included 9 patients at stage 0 COPD, 7 with mild and 3 with moderate COPD. Lung There was no significant differences between these parameters at the study time points.
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A c c e p t e d m a n u s c r i p t The difference between nitrite ( Fig. 2A) The difference between thiol (RSH) concentration in exhaled breath condensate (EBC) of COPD patients before -initial, 30 min and 180 min. after 3 ml nebulized N-acetylcysteine and placebo.
Relative RSH concentration is a difference between individual levels after nebulized NAC and PL. Underlined are median of thiol concentration increase after NAC with subtracted placebo values at respective time points. * p=0.009 vs. initial 39.
